Brentuximab vedotin clinical trials
6 indexed studies · 3 currently recruiting
- Active not recruitingPHASE3
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
This study is for people in the UK with a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL) that has returned or not responded to previous treatments. It aims to see if adding an experimental drug, brentuximab vedotin, to two existing treatments (rituximab and lenalidomide) works better than the two existing treatments alone.
For: Diffuse Large B-cell LymphomaUnited States · Australia · Belgium - CompletedPhase II
Brentuximab vedotin In patients with Hodgkin lymphoma
This study tests a targeted drug called brentuximab vedotin for people with classical Hodgkin lymphoma. It is designed for patients who cannot have standard chemotherapy due to older age, general frailty, or other health problems affecting their heart or lungs. It aims to offer an effective, gentler alternative treatment.
For: Topic: National Cancer Research Network; Subtopic: Lymphoma; Disease: Lymphoma (Hodgkin's)United Kingdom · England · Scotland - Active not recruitingPHASE3
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
This study compares two immunotherapy drugs (nivolumab or brentuximab vedotin) when used with chemotherapy for newly diagnosed, advanced Hodgkin lymphoma. It aims to see which combination works best at shrinking the cancer and keeping it away.
For: Ann Arbor Stage III Hodgkin Lymphoma · Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma · Ann Arbor Stage III Mixed Cellularity Classic Hodgkin LymphomaUnited States · Canada · Puerto Rico - RecruitingPHASE2
Pembrolizumab and Brentuximab Vedotin vs GDP and Stem Cell Transplant for Relapsed/Refractory Hodgkin Lymphoma
This study looks at new treatments for Hodgkin lymphoma that has returned or not responded to previous treatment. It compares two newer drugs, pembrolizumab and brentuximab vedotin, with the standard treatment to see if they work better.
For: Hodgkin LymphomaAustralia · Canada - RecruitingPHASE2
Open Label Extension Study of Brentuximab Vedotin in Early dcSSc
This study looks at Brentuximab vedotin for severe scleroderma. It's for people who improved on the treatment before but whose condition worsened after stopping it. Researchers want to see if restarting the treatment is safe and helpful.
For: Diffuse Cutaneous Systemic SclerosisCanada - RecruitingPHASE3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
This study is for people with early-stage Hodgkin Lymphoma. It compares two chemotherapy treatments, ABVD and A2VD, to see which works best. Treatment is adjusted based on scans, and patients are followed for at least 5 years.
For: Hodgkin LymphomaUnited States · Australia · Belgium